Mendus is a clinical-stage biopharmaceutical company dedicated to transforming immunotherapy for myeloid blood cancers. We are developing novel cancer immunotherapies aimed at controlling residual disease and improving long-term outcomes while preserving health and quality of life. Based in Sweden and the Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
| Website | https://mendus.com/ |
| Employees | 24 (0 on RocketReach) |
| Address | Västra Trädgårdsgatan 15, Stockholm, Stockholm County 11153, SE |
| Phone | +46 8 732 84 00 |
| Industry | Biotechnology Research |
| Keywords | Cancer Treatment, Cancer Survival, Quality Of Life, Immunotherapy, Cancer Research, Oncology, Clinical Trials, Cancer Care, Cell Therapy, Immunology, Precision Medicine, Drug Development, Biotechnology, Medical Research, Patient Care, Cancer Prevention, Healthcare |
| Competitors | Gilead Sciences, アステラス製薬（株）, Bristol Myers Squibb, Receptos, a wholly-owned subsidiary of Celgene, Amgen, Merck & Co., Inc., Novartis, AstraZeneca, Sanofi, Regeneron +43 more (view full list) |
Looking for a particular Mendus AB employee's phone or email?
Mendus AB Questions
Mendus AB is based in Stockholm, Stockholm County.
Related Companies
G2Crowd Trusted
300K+
Plugin Users
